Saturday 17 October 2026
Export BDSX’s income statement to Excel — free account
Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
23.66
1.05
−4.25%
Follow BDSX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 5 | 5 |
| (302.55%) | (383.09%) | (316.53%) | (540.01%) | ||
| (41.30%) | (38.18%) | (35.34%) | (30.33%) | ||
ROIC |
(70.66%) | (67.00%) | (51.87%) | (49.60%) | |
Return on Tangible Assets |
(97.11%) | (88.39%) | (63.14%) | (53.31%) | |
Average Days of Receivables |
57.70 | 37.27 | 36.08 | 32.31 | |
Free Cash Flow per Share |
(3.91) | (3.14) | (2.61) | (1.98) | |
Free Cash Flow |
(29.33) | (23.67) | (25.25) | (20.40) | |
Capital Expenditures |
(1.18) | (0.40) | (0.41) | (0.57) | |
| Other line items | |||||
Cash ROIC |
(47.30%) | (37.01%) | (31.10%) | (23.73%) | |
Accounts Receivable Turnover |
7.74 | 10.03 | 11.21 | 12.43 | |
Accounts Payable Turnover |
5.26 | 6.34 | 5.24 | 7.02 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
81.58 | 67.24 | 77.38 | 43.78 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
14.40% | 13.56% | 12.92% | 11.93% | |
Selling, General and Administrative Expense of Revenue |
105.76% | 98.92% | 95.07% | 90.57% | |
Share Based Compensation of Revenue |
5.40% | 4.68% | 4.46% | 3.95% | |
Interest Coverage |
(4.39) | (3.61) | (3.11) | (2.55) | |
Operating CF/Net income |
0.71 | 0.66 | 0.78 | 0.71 | |
Depreciation/Fixed assets |
0.28 | 0.28 | 0.29 | 0.29 | |
Capex/Depreciation |
(0.17) | (0.06) | (0.06) | (0.08) | |
Revenue per Share |
10.69 | 11.72 | 9.95 | 10.00 | |
Operating CF per Share |
(3.75) | (3.08) | (2.57) | (1.93) | |
Capex per Share |
(0.16) | (0.05) | (0.04) | (0.06) | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.01 |
Columns are period end dates